Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B338- Other specified viral diseases
Conditions
Interventions
Intervention1: ASPIRIN, ATORVASTATIN, NICORANDIL: all drugs will be given orally
ASPIRIN 325 mg stat f/b 75 mg od
atorvastatin 80 mg stat f/b 40 mg od hs
nicorandil 10 mg stat f/b 5 mg bd for 10 da
Sponsors
Dr Ambudhar Sharma
Eligibility
Inclusion criteria
Inclusion criteria: Age >18years A person with laboratory confirmation of covid -19, irrespective of signs and symptoms, Patients with moderate clinical severity(pneumonia with no signs of severe disease) and severe (severe pneumonia and mild ARDS) requiring hospital admission , Consenting to participate for the trial
Exclusion criteria
Exclusion criteria: Documented significant liver disease / dysfunction (AST/ALT > 240), Myopathy and Rhabdomyolysis (CPK > 5x normal) , Allergy or intolerance to statins , Allergy or intolerance to aspirin , Patients taking the following medications: cyclosporine, HIV protease inhibitors, hepatitis C protease inhibitor, telaprevir, fibric acid derivatives (gemfibrozil), niacin, azole antifungals (itraconazole, ketoconazole) clarithromycin and colchicine , Prior statin use (within 30 days), Prior aspirin use (within 30 days) , History of active GI bleeding in past three months ,Coagulopathy , Thrombocytopenia (Platelet count ,Moderate and severe ARDS, renal dysfunction, altered mental status, shock, thrombotic manifestation ,sepsis at presentation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Progression to any of following In-hospital mortality , moderate and severe ARDS , shock ,Occurrence of thrombotic events(VTE, ACS, ischemic stroke),Cardiac injury (acute heart failure,dysrythmia),Acute kidney injury,Impaired counciousness,Length of hospital stay ,Length of mechanical ventilation (invasive plus noninvasive) Timepoint: 10 days or till hospital discharge whichever is later | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Change in serum markers (CRP, D â??dimer, S ferritin). Individual occurrence of any of following In-hospital mortality Progression to mod or severe ARDS ,Progression to shock ,Occurrence of thrombotic events(VTE, ACS, ischemic stroke),Cardiac injury (acute heart failure,dysrythmia) ,Acute kidney injury,Impaired counciousness Timepoint: 10 days or till hospital discharge whichever is later | — |
Countries
India
Contacts
Public ContactAmbudhar sharma
Dr. RPGMCTanda
Outcome results
None listed